Osaic Holdings
GLUE icon

Osaic Holdings’s Monte Rosa Therapeutics GLUE Stock Holding History

Osaic Holdings’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.2K Buy
2,651
+1,057
+66% +$20K ﹤0.01% 5295
2026
Q1 		$26.2K Sell
1,594
-1,824
-53% -$34.9K ﹤0.01% 5687
2025
Q4 		$53.6K Buy
3,418
+933
+38% +$12.6K ﹤0.01% 5184
2025
Q3 		$15.3K Buy
2,485
+201
+9% +$1.06K ﹤0.01% 6108
2025
Q2 		$10.3K Buy
2,284
+1,126
+97% +$5.02K ﹤0.01% 6127
2025
Q1 		$5.37K Sell
1,158
-2,699
-70% -$16.6K ﹤0.01% 6136
2024
Q4 		$26.8K Buy
3,857
+2,799
+265% +$21K ﹤0.01% 5132
2024
Q3 		$5.61K Buy
1,058
+12
+1% +$61 ﹤0.01% 6144
2024
Q2 		$3.91K Buy
1,046
+646
+162% +$3.29K ﹤0.01% 6292
2024
Q1 		$2.82K Hold
400
– – ﹤0.01% 6333
2023
Q4 		$2.26K Buy
+400
New +$1.57K ﹤0.01% 6499

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings's GLUE Position: Q2 2026 in Review

Osaic Holdings increased its Monte Rosa Therapeutics (GLUE) stake by 66% in Q2 2026, buying an estimated $20K and bringing the position to 2,651 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5295.

Osaic Holdings first reported a position in GLUE in Q4 2023 and has held it in 11 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Osaic Holdings held 2,651 shares of Monte Rosa Therapeutics worth $64.2K as of Q2 2026.
  • Osaic Holdings bought 1,057 Monte Rosa Therapeutics shares in Q2 2026, an estimated $20K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5295 holding.
  • Osaic Holdings first reported a position in Monte Rosa Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.